Bris­tol My­ers nabs ap­proval for Op­di­vo com­bo as first-line blad­der can­cer treat­ment

Bris­tol My­ers Squibb won an­oth­er ap­proval for its block­buster can­cer drug Op­di­vo, this time to treat a type of blad­der can­cer in com­bi­na­tion with chemother­a­pies, the FDA an­nounced Wednes­day.

The FDA ap­proved nivolum­ab, mar­ket­ed as Op­di­vo, to be ad­min­is­tered in com­bi­na­tion with the chemother­a­pies cis­platin and gem­c­itabine to treat adults with un­re­sectable or metasta­t­ic urothe­lial car­ci­no­ma. The ap­proval was based on pos­i­tive re­sults from BMS’ Check­Mate-901 tri­al, which eval­u­at­ed over­all sur­vival and pro­gres­sion-free sur­vival in about 600 pa­tients who had not pre­vi­ous­ly re­ceived treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER